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Abstract
Purpose of Review To evaluate the evidence supporting the use of exercise training as a
treatment strategy to reduce risk of cardiovascular disease (CVD) in cancer populations
and to provide an overview of the use of cardiac rehabilitation (CR) in cancer patients
and survivors.
Recent Findings A recent scoping review suggests that CR-style interventions are feasible
in cancer patients, but more evidence is needed to establish the benefits of this approach.
Summary Cancer survivors are at increased risk of CVD as a result of side effects of cancer treatment, shared risk factors for cancer and CVD, and effects from the cancer itself.
Aerobic exercise training improves peak V O2, but few models exist to support widespread
incorporation of exercise training into cancer care. CR could provide infrastructure to support the incorporation of exercise in cancer populations, but data are limited regarding
the feasibility or benefits of CR in cancer patients.
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Introduction
As advancements are made in early detection of cancer
and therapeutic options improve, life expectancy after
a cancer diagnosis has risen, and the number of cancer survivors continues to grow [1]. The growth in this
segment of the population has highlighted the adverse
effects of cancer and associated cancer therapeutics on
the cardiovascular system and the need for cardioprotective interventions that help to mitigate these effects.
Exercise training has been identified as an appealing
intervention to reduce the risk of cardiovascular (CV)
disease in patients with cancer, as it is relatively safe
and well-tolerated, and its effects are systemic and target multiple organ systems. Exercise training is a type of
physical activity that is defined as planned, purposeful,
repetitive movement with the purpose of improving

physical fitness [2]. Observational studies show that
higher levels of physical activity are associated with
lower cancer risk and improved cancer outcomes, and
interventional studies have demonstrated that exercise improves cardiorespiratory fitness and other end
points in cancer patients during and after cancer treatment [3, 4, 5•]. Here, we provide a focused review of
the evidence supporting the use of exercise training as
a treatment strategy to reduce the morbidity of cancer
and cancer treatment, as well as to mitigate CV risk in
cancer populations. In addition, we review the use of
cardiac rehabilitation (CR) to help deliver a multidisciplinary exercise intervention to cancer patients and
survivors.

Adverse Effects of Cancer/cancer Therapeutics On
the Cardiovascular System
Cancer survivors are at increased risk of adverse CV events during their treatment course and in the years following [6, 7]. This elevated risk stems from
cardiotoxic and metabolic effects of therapies (such as radiation, chemotherapy, and targeted therapies), weight gain and physical deconditioning
due to inactivity during and after treatment, shared risk factors for cancer
and cardiovascular disease (e.g., obesity and inactivity), and effects from the
cancer itself such as malnutrition, cachexia, and sarcopenia [6, 8–12]. The
data indicate that cancer survivors living at least 5 years beyond their diagnosis have a 1.3- to 3.6-fold increased risk of CV-specific mortality and a
1.7- to 18.5-fold increased incidence of CV risk factors such as hypertension,
diabetes mellitus, and dyslipidemia compared with cancer-free age-matched
controls [4, 13, 14]. Additionally, while decreases in cardiac function and
the development of heart failure symptoms are important sequelae of cancer
therapies and should be appropriately screened for, it is also important to
recognize that there is damage to the entire cardiovascular-skeletal muscle
axis [6, 7, 9, 10].
Cardiorespiratory fitness (CRF), as measured by peak oxygen uptake
(VO2), is an integrated measurement of cardiovascular, respiratory, and skeletal muscle capacity and function [15]. Cancer therapy is associated with a
decline in CRF of 5–26%, depending on the cancer type and therapeutic exposure [16, 17•]. This drop in CRF is associated with worse patient outcomes,
both in terms of patient reported metrics (such as fatigue, anxiety, depression,
function, and quality of life) and subsequent CV disease incidence and overall
survival [8, 18]. For example, a meta-analysis of 71,654 cancer patients and
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2002 cases of cancer mortality found that patients with an intermediate or
high level of CRF had a lower risk of overall cancer mortality as compared to
patients with lower CRF (relative risk [RR] 0.80 95% confidence interval [CI]
0.67–0.97, and RR 0.55, 95% CI 0.47–0.65, respectively) [19].

Observational Evidence of Physical Activity and Cancer
Observational evidence increasingly demonstrates an association between
higher levels of physical activity (PA), one of the few lifestyle behaviors
known to improve CRF, and lower levels of developing and dying from cancer.
Hundreds of epidemiologic studies have found strong evidence of an association between higher levels of PA and lower incidence of cancer. For example,
a pooled study including the data from 12 cohorts consisting of more than
1.44 million individuals in the USA and Europe found that higher levels
of leisure time PA were associated with decreased rates of 13 cancers, with
most relationships remaining significant in multivariate analyses adjusted for
body mass index [20]. The US Department of Health and Human Services
(HHS) 2018 Physical Activity Guidelines Advisory Committee (PAGAC) systematically reviewed the literature evaluating the relationship between PA and
cancer risk and identified 45 systematic reviews, meta-analyses, and pooled
analyses on this topic, in aggregate including several million participants
(https://health.gov/sites/default/files/2019-09/PAG_Advisory_Committee_
Report.pdf). A systematic review and meta-analysis by McTiernan et al. summarizing these data demonstrated a significant association between highest
versus lowest physical activity levels and reduced risks of bladder, breast,
colon, endometrial, esophageal adenocarcinoma, renal, and gastric cancers,
with relative risk reductions ranging from 10 to 20% [20]. In several cases, the
relationship was dose-dependent relationship. The analysis found insufficient
evidence to establish a relationship between physical activity and other cancers including hematologic, head and neck, ovarian, pancreatic, and prostate.

Physical Activity and Cancer Recurrence and Mortality
While epidemiologic evidence showing the inverse relationship between PA
and cancer risk is long-standing and expansive, the relationship between PA and
cancer outcomes like recurrence and mortality has only been recognized more
recently. Breast, colorectal, and prostate cancers are the most widely studied in
this setting. In these cancers, higher levels of PA after cancer diagnosis are associated with a 37–48% lower risk of all-cause mortality [21•]. A meta-analysis
by Friedenreich et al. compiled 136 studies across cancer types and examined
cancer-specific mortality in patients with highest levels of PA levels versus those
with lowest [22]. Most of the studies focused on mixed cancers (38 studies),
breast cancer (39 studies), colorectal cancer (19 studies), or prostate cancer (9
studies). Cancer-specific mortality was lower in individuals who engaged in
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the highest vs lowest amount of PA before diagnosis (HR 0.82, 95% CI 0.79 to
0.86) and after diagnosis (HR 0.63, 95% CI 0.53–0.75). The authors found evidence that higher physical activity levels before cancer diagnosis were protective
against cancer-specific mortality in patients with breast (HR = 0.86, 95% CI 0.78
to 0.94), colorectal (HR = 0.80, 95% CI 0.74 to 0.87), hematologic (HR = 0.82,
95% CI 0.76 to 0.90), liver (HR = 0.78, 95% CI 0.66 to 0.92), lung (HR = 0.81,
95% CI 0.75 to 0.87), and stomach cancer (HR = 0.74, 95% CI 0.58 to 0.95),
and higher levels of PA after cancer diagnosis were associated with lower cancerspecific mortality in patients with breast (HR = 0.63, 95% CI 0.53 to 0.75),
colorectal (HR = 0.62, 95% CI 0.44 to 0.86), and prostate cancer (HR = 0.70,
95% CI 0.55 to 0.90) [22].

Randomized Trials Using Exercise Training As an Intervention
in Cancer Populations
Despite the large body of observational evidence linking higher levels of PA to
lower cancer risk and better cancer outcomes, to date, there are no data from randomized clinical trials (RCTs) testing the benefit of exercise training on cancer
related mortality or overall survival. However, hundreds of interventional trials
have tested the effect of exercise training on other endpoints such as patientreported outcomes and CRF [5•, 23]. Notably, there is significant heterogeneity
in the type, frequency, and intensity of exercise training that has been studied
in the cancer populations, with some evidence that benefits may be strongest in trials that have incorporated supervised exercise training [22, 24, 25].
Exercise training during and after cancer treatment improves patient-reported
outcomes such as fatigue, mood, and quality of life [26–28]. For example, a
meta-analysis of 113 studies found that exercise and psychological interventions
(both independently and in conjunction with one another) improved cancerrelated fatigue during and after treatment (P < 0.001), whereas pharmacologic
intervention did not [29]. Similarly, meta-analyses demonstrate that exercise
interventions during and after cancer treatment lead to improvements in selfreported physical function in mixed cancers (SMD 0.22, 95% CI 0.13 to 0.32),
as well as in patients with breast (SMD 0.14, 95% CI 0.01 to 0.27) and colorectal
(SMD 0.26, 95% CI 0.04 to 0.48) cancers [30, 31].

Randomized Trials Testing the Impact of Exercise Training On Cancer Recurrence and Mortality
Although there are currently no data from RCTs testing the impact of an
exercise intervention on cancer recurrence or mortality, a number of ongoing or recently completed trials will test the impact of exercise interventions,
with or without a dietary component, on disease-free and overall survival
in individuals with cancer (Table 2). Two of these studies, the Colon Health
and Life-Long Exercise Change (CHALLENGE) trial and the INTERVAL GAP-4
trial, focus specifically on the impact of exercise training on cancer outcomes

Curr Treat Options Cardio Med (2022) 24:183-197

187

(Table 1). CHALLENGE will randomize 962 patients with high-risk stage
II or III colon cancer who recently completed adjuvant chemotherapy to a
36-month exercise program or to a health education control group, with the
primary goal of evaluating the impact of the exercise intervention on diseasefree survival. One-year feasibility results of the CHALLENGE trial were published after 273 participants had completed the first year of the exercise or
control program, demonstrating that individuals randomized to the exercise
program increased weekly exercise by 15.6 MET (metabolic equivalents of
task)-hours vs 5.1 MET-hours in the health education group [mean difference 10.5 MET-hours/week; 95% CI 3.1–17.9; P = 0.002]. Exercise participants (vs controls) also experienced improvements in peak VO2 (P = 0.068),
6-min walk (P < 0.001), 30-s chair stand (P < 0.001), 8-foot get up-and-go
(P = 0.004), and sit-and-reach (P = 0.08) tests [32]. The INTERVAL GAP-4 trial
focuses on individuals with advanced cancer and will randomize 866 men
with castration-resistant metastatic prostate cancer to high-intensity aerobic
and resistance training versus self-directed training, with a primary endpoint
of the overall survival. Enrollment is currently ongoing [33]. There are also a
number of phase III RCTs testing the impact of exercise within a multicomponent lifestyle intervention on cancer recurrence and morality in individuals
with breast and ovarian cancer (Table 2) [32–37]. These studies will better
define the role of exercise training, by itself and as a part of broader lifestyle
change, in cancer treatment over the coming years.

Exercise and Cardiovascular Outcomes in Cancer Patients
Several RCTs have tested the impact of exercise training on CRF during and
after cancer treatment [17•, 38, 39, 40]. Studies have tested aerobic training interventions, with or without a resistance training component, in
patients with a variety of cancer types. Notably, several trials specifically
enrolled patients to exercise training interventions during treatment with
anthracyclines and other potentially cardiotoxic chemotherapy agents [41].
Overall, these studies have demonstrated that exercise training is a safe
and effective strategy to improve CRF in cancer patients [41]. The largest
meta-analysis on this topic included 48 RCTs, accounting for 3632 cancer
patients randomized to exercise training during and after cancer treatment
[17•]. The results demonstrated that aerobic exercise training interventions
led to a significant increase in CRF (+ 2.80 mL.kg−1.min−1) as compared
with no change (+ 0.02 mL.kg−1.min−1) in controls (weighted mean differences, + 2.13 mL.kg−1.min−1; 95% CI, 1.58 to 2.67; I2, 20.6; P < 0.001) [17•].
There is less evidence regarding the role of exercise in the prevention of
treatment-associated cardiotoxicities such as congestive heart failure and myocardial infarction. One preclinical mouse model found that the initiation of
exercise after the administration of doxorubicin therapy promoted recovery of
left ventricular ejection fraction and fractional shortening [42], but a similar
study showed no effect [43]. A few small human studies have also evaluated
the impact of exercise training during cardiotoxic chemotherapy on markers

LIVES trial [37]

BWEL trial [36]

Stage II-III HER2/negative breast cancer,
BMI > 27kg/m2
Stage II–IV ovarian cancer

Stage II or III colorectal cancer s/p adjuvant
chemotherapy
INTERVAL GAP-4 trial [33] Metastatic castrate-resistant prostate
cancer
SUCCESS-C trial [34]
Stage II-III HER2/neu negative breast
cancer, BMI 24-40 kg/m2
DIANA-5 trial [35]
Stage I-III breast cancer; unfavorable
metabolic factors or triple negative cancer

CHALLENGE trial [63]

Patient population

N = 1070

N = 3136

N = 1208

Diet + moderate-low intensity exercise
intervention

High intensity aerobic and resistance
training
Lifestyle intervention program aimed at
moderate weight loss
Lifestyle intervention program
(macrobiotic, mediterranean
diet + exercise)
Supervised weight loss program

N = 866
N = 3547

36-month physical activity program

N = 962

Size (n) Intervention

Progression-free survival

Disease-free survival

Breast cancer recurrence

Disease-free survival

Overall survival,
disease-free survival
Overall survival

Outcome

Table 1  Ongoing randomized control trials examining the effects of lifestyle interventions on various cancer/overall survival endpoints
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41

20

30

Hubbard et al. [60]

De Jesus et al. [66]

Rothe et al. [67]

Breast cancer patient
Single arm study
with fatigue
post adjuvant
chemotherapy
Lymphoma patients
Single arm study
post autologous HSCT

Post-surgical colorectal RCT
cancer survivors

Cancer survivors w/
Single arm feasibility
mixed primary
study
malignancy site
(22% breast,
19% prostate, 8%
colorectal, 3% lung,
8% hematologic, 39%
other), diagnosed
within 2 years of
study start
280 Cancer survivors w/
Single arm study
mixed primary
malignancy site (68%
breast, 2% prostate,
2% colorectal,
3% lung, 3%
hematological, 22%
other)

Dittus et al. [65]

62

Study design

Young-McCaughan
et al. [64]

Cancer type

N

Author/year

Table 2  Interventional studies of cardiac rehabilitation in cancer patients

Standard CR

Standard CR

Standard CR

Modified CR

Modified CR

Intervention
type

Results

12 weeks
Significant improvements:
2 sessions/week - 6MWT (534.2 ± 171 m to
582.7 ± 157.2 m, P = 0.03)
- Strength: chest press and leg
press (each P < 0.0001)
- Fatigue (15.7 ± 12.2 to
10.0 ± 11.8, P < 0.0001)
- Depression (5.34 ± 4.0, to
3.7 ± 3.5, P < 0.0001)
- Anxiety (2.87 ± 3.5 to 2.34 ± 3.2,
P < 0.042)
No significant change in CRF
6–12 weeks
Study met primary feasibility
1–3 sessions/
endpoint (62% of participants
week
completed program per protocol)
16 weeks
No significant differences
3 sessions/week in body composition, CRF,
fatigue, minutes of PA, anxiety,
depression, or QOL
8 weeks
Significant improvements:
1 session/week - Grip strength (38 kg ± 13 to
40 kg ± 12, P < 0.005)
- Gait speed (1.35 m/s ± 0.22 to
1.47 m/s ± 0.22, P = 0.02)
- 6MWT (484 m ± 95 to 532 m ± 98,
P = 0.001)

12 weeks
Significant improvements:
2 sessions/week - CRF (7.4 ± 2.1METs to 8.4 ± 2.1
METs, P < 0.001)
- QOL (46.8 ± 8.62 to 44.3 ± 10.12,
P = 0.03)
No significant change in minutes
of PA

Intervention
duration
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20

25

Hubbard et al. [68]

Zvinovski et al. [69]

Single arm feasibility
study

Single arm study

Study design

Standard CR

Modified CR

Modified CR

Intervention
type

14 weeks

12 weeks

22 weeks
1 session/week

Intervention
duration

CRF cardiorespiratory fitness, PA physical activity, QOL quality of life, 6MWT 6-min walk test, CR cardiac rehabilitation

Modified CR, program in which oncology patients participated in a separate modified CR/exercise program

Standard CR, program in which oncology patients participated alongside cardiac patients in traditional CR structure

Breast cancer survivors Single arm feasibility
study

Early-stage breast
cancer patients postsurgery

152 Early-stage breast
cancer survivors

Dolan et al. [61]

Cancer type

N

Author/year

Table 2  (continued)

Significant improvements:
- CRF (21 mL/kg/min ± 6 to
24 mL/kg/min ± 7, P < .001)
- QOL (101.5 ± 23.9 to 110.6 ± 20,
P < .001)
- Depression (13.3 ± 9.4 to
11.8 ± 8.7, P = 0.019)
No significant change in pain
Patients who were provided with
options for post-treatment
exercise programs were more
likely to choose telephone-based
PA consultations or referral to a
leisure center over in-person CR
programs
Significant improvements:
- PA (mean Δ13.2; P < 0.001)
- Fatigue (mean Δ − 1.7, P = 0.007)
- QOL (Δ5.66, P = 0.008)
Study did not meet primary
feasibility goal of 80% of
participants completing at least
30/36 sessions
No significant change in CRF

Results
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of subclinical cardiac damage. A secondary analysis of the OPTiTrain Trial
included 88 women with breast cancer who were undergoing treatment with
an anthracycline and were randomized to 16 weeks of high-intensity interval
training, plus either aerobic or resistance training, or to usual care. The results
demonstrated that exercise did not impact levels of troponin immediately
following the completion of chemotherapy but did result in lower levels of
natriuretic peptides (BNP), used to diagnose heart failure, at 1-year followup [44]. Another trial randomized 24 women receiving doxorubicin for early
breast cancer to an acute bout of aerobic exercise immediately before chemotherapy infusion or to usual care [45]. Exercise did not impact doxorubicinrelated change in left ventricular mechanics (longitudinal strain or twist),
or cardiac troponin, but women randomized to exercise were less likely to
experience decreased cardiac output, increased resting heart rate, or decreased
systemic vascular resistance as compared with controls (all P < 0.01) [45].
A number of ongoing studies are also examining the ability of exercise
training to prevent cancer therapy-associated cardiotoxicity. The caloric
restriction and exercise protection from anthracycline toxic effects (CREATE)
trial will evaluate the impact of exercise and caloric restriction on MRI-derived
left ventricular ejection fraction reserve (peak exercise LVEF-resting LVEF), as
well MRI-derived measures of cardiac, aortic, and skeletal muscle structure
and function, circulating NT-proBNP, CRF, and patient-reported outcomes
[46]. The trial will randomize 56 women with early breast cancer scheduled
to receive an anthracycline to one of the 3 groups: [1] exercise, participants
will complete a single, 30-min, vigorous-intensity, aerobic exercise session
24 h before each chemotherapy cycle; [2] caloric restriction, participants will
consume a diet that includes 50% of their caloric needs for 48 h prior to
each chemotherapy cycle; or [3] usual care [46]. A second study, the Tailored
Therapeutic Exercise and Recovery Strategies (ATOPE) trial, will randomize
120 women undergoing cardiotoxic treatment for early breast cancer to a tailored exercise training program delivered before and during cancer treatment
or to usual care and will evaluate the impact of the exercise training on left
ventricular ejection fraction, as well as other biomarkers and patient-reported
outcomes [47]. These trials will further define the role of exercise training in
preventing chemotherapy-induced cardiotoxicity.

Cardiac Rehabilitation and its Application in the Cancer
Population
Cardiac rehabilitation (CR) is an early outpatient (often called phase II)
secondary prevention program recognized as integral to the comprehensive
care of patients with CVD [48–51]. The model of CR has evolved over the
past four decades, as the role of exercise as an integral part of secondary
CVD prevention has been better studied and understood. The CR model
places aerobic exercise at its core, while also incorporating multidisciplinary CVD risk modification strategies including medication management,
nutrition and weight loss, smoking cessation, and psychosocial counseling.
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The benefits of CR for patients with coronary artery disease—including
those with acute coronary syndrome, recent coronary revascularization, or
stable angina pectoris—are broad and well-established [51–55]. The data
from RCTs demonstrate that CR leads to a 10–25% reduction in mortality
over 1–3 years and an almost 30% reduction in rates of rehospitalization
over 1 year, in addition to increasing CRF and patient quality of life in
individuals with coronary artery disease and in those with congestive heart
failure [56–58]. Much of this benefit is thought to stem from the 15–30%
increase in CRF that results from participation in the supervised program,
as well as the associated favorable physiologic effects that such a regimen
has on coronary and peripheral endothelial function, insulin resistance,
blood pressure, and systemic inflammation [55, 57].
Given the effectiveness of CR and the significant infrastructure that
has been built around it, CR has been advanced as a potential framework
for delivering multidisciplinary rehabilitation care to cancer patients and
survivors [59]. However, only a few small trials have evaluated the feasibility or benefits of applying the CR model to cancer populations (Table 2),
and only one of these studies, a pilot trial of CR in patients with colorectal
cancer, employed a randomized design. In that study, 41 patients who
had undergone surgery for stage I–III colorectal cancer were randomized
to referral to a CR program or to usual care [60]. The CR program met
the protocol-specified definition of acceptability, with 62% of participants
completing the intervention as per protocol, and no adverse events were
reported. The remaining studies of CR in cancer patients have used quasiexperimental designs, evaluating changes in outcomes before and after
participation in CR programs or comparing effects of CR to historical controls. For example, Dolan et al. retrospectively reviewed medical records
from 152 breast cancer survivors taking part in a tailored exercise program,
including both aerobic and resistance training exercise performed once
weekly in a group setting supervised by CR staff, and found that patients
who took part in the program experienced significant improvements in
CRF (P < 0.01) and patient-reported outcomes (PROs; P < 0.05 for all) [61].
Although these preliminary data are promising, larger-scale trials employing randomized designs are needed to provide more robust evidence on
the efficacy of utilizing CR in cancer patients.

Cardio‑oncology Rehabilitation (CORE) Model and Future
Directions
A 2019 American Heart Association scientific statement endorsed by the American Cancer Society laid out the framework for a cardio-oncology model of
rehabilitation (CORE) based on the CR model [4]. As in the cardiac patient
population, CORE would serve as a structured way to incorporate exercise training to increase CRF in patients who are undergoing or who have previously
undergone cancer treatment, while also incorporating comprehensive risk factor
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modification, behavioral/lifestyle intervention, and psychological and community support.
The application of a standardized exercise intervention model in cancer
populations would require significant work to identify the most efficacious
and practical exercise training model or models. It is notable that some of the
trials described above testing the feasibility and benefits of CR or CR-like interventions in cancer patients have delivered a standard CR program to cancer
patients alongside cardiac patients, while others have used the CR infrastructure
but have created tailored stand-alone oncology programs. Both approaches have
advantages and disadvantages. Utilizing existing CR programs provides greater
potential for dissemination, given that these programs exist throughout the
USA, while building an oncology-specific program provides the opportunity
to customize the program to fit the unique medical and psychosocial needs of
cancer patients.
More broadly, the implementation of a CR model in cancer patients will present a unique set of challenges, despite the existing framework of this program
for the CVD population and the evidence supporting the value of exercise in
patients with cancer. Widespread, systematic adoption will require buy-in from
both the multidisciplinary care team and the patient. While significant progress
has been made in the recognition of exercise as an important part of survivorship care and CVD risk factor modification, education and proper pipelines
for referral will be imperative for ensuring broad uptake of CR. Evidence-based
discussions between the care team and patients regarding the benefits of exercise will be an important aspect of widespread adoption, and the education of
providers will help catalyze meaningful discussions with patients. In addition,
patients may be hesitant to participate in a structured exercise program due to
a variety of factors including time constraints, side effects from therapy, and
struggles with transportation and funding. Finally, policy barriers such as lack
of insurance reimbursement need to be addressed [62]. Looking forward, critical data from high-quality randomized controlled trials testing the efficacy and
acceptability of CR in cancer populations will be needed to support widespread
dissemination.

Conclusions
Cancer patients are at increased risk of CVD, due to the effects of cancer treatment and to shared risk factors for malignancy and CVD. Higher levels of
physical activity have been linked to lower cancer risk and better outcomes
in patients diagnosed with early-stage malignancies, and RCTs have demonstrated that exercise training during and after cancer treatment reduces
treatment-related side effects and improves quality of life in cancer patients.
Exercise training also improves CRF in cancer patients, but less is known
regarding the efficacy of exercise in preventing cardiac toxicity of cancer treatment. Structured exercise training programs are needed to better disseminate exercise to cancer patients. Though data to support optimization is still
needed, the CORE model provides a promising approach to delivering a
bundled, interdisciplinary intervention with a focus on supervised rigorous
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aerobic exercise training to cancer patients using the well-established framework of traditional CR, with long-term goals of decreasing cardiovascular
events and enhancing survivorship in cancer patients.
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